Novel models for assessing bloodbrain barrier drug permeation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 6, 2012, Pages 647-653

  Geldenhuys, Werner J ^a   Allen, David D ^b   Bloomquist, Jeffrey R ^c  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Animal models; HTS models; LogBB; Vertebrate

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT;

ANIMAL MODEL; BLOOD BRAIN BARRIER; COST; DROSOPHILA MELANOGASTER; DRUG PENETRATION; HIGH THROUGHPUT SCREENING; LOCUST; NONHUMAN; REVIEW; ZEBRA FISH;

ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; DROSOPHILA MELANOGASTER; GRASSHOPPERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; ZEBRAFISH;

ANIMALIA; DANIO RERIO; DROSOPHILA MELANOGASTER; LOCUSTA MIGRATORIA; VERTEBRATA;

EID: 84862070073     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.677433     Document Type: Review

References (64)

1. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12(1-2):54-61 (Pubitemid 46014479)
2. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery anddevelopment. Nat Rev Drug Discov 2007;6(8):650-61 (Pubitemid 47202487)
3. Mahringer A, Ott M, Reimold I, et al. The ABC of the blood-brain barrier - regulation of drug efflux pumps.Curr Pharm Des 2011;17(26):2762-70
4. van de Waterbeemd H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr Opin Drug Discov Dev 2002;5(1):33-43
5. van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat RevDrug Discov 2003;2(3):192-204 (Pubitemid 37361664)
6. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7(2):165-82
7. Rice A, Liu Y, Michaelis ML, et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J Med Chem2005;48(3):832-8 (Pubitemid 40209105)
8. Deftereos SN, Andronis C, Friedla EJ, Persidis A. Drug repurposing and adverse event prediction using high-throughputliterature analysis. Wiley Interdiscip Rev Syst Biol Med 2011;3(3):323-34
9. Pan SY, Pan S, Yu ZL, et al. Newperspectives on innovative drug discovery: an overview. J Pharm PharmSci 2010;13(3):450-71
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85 (Pubitemid 36279392)
11. Morgan S, Grootendorst P, Lexchin J, et al. The cost of drug development: a systematic review. Health Policy 2011;100(1):4-17
12. Dove A. Drug screening-beyond the bottleneck. Nat Biotechnol 1999;17(9):859-63
13. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003;8(20):927-33 (Pubitemid 37230012)
14. Williams CH, Hong CC. Multi-step usage of in vivo models during rational drug design and discovery. Int J Mol Sci2011;12(4):2262-74
15. Liebner S, Czupalla CJ, Wolburg H. Current concepts of blood-brain barrier development. Int J Dev Biol 2011;55(4-5):467-76
16. Mittapalli RK, Manda VK, Adkins CE, et al. Exploiting nutrient transporters at the blood-brain barrier to improve braindistribution of small molecules. Ther Deliv 2011;1(6):775-84
17. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011;13:e19
18. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiology Dis 2010;37(1):13-25
19. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol2005;25(1):5-23 (Pubitemid 40558582)
20. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40(3):648-77
21. Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point ofview. Anat Rec B New Anat 2006;289(1):3-8 (Pubitemid 43219973)
22. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47-62 (Pubitemid 20327537)
23. Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16(5-6):270-7
24. Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol 2011;686:133-48
25. Abbott NJ, Dolman DE, Patabendige AK. Assays to predict drug permeation across the blood-brainbarrier, and distribution to brain. Curr Drug Metab 2008;9(9):901-10
26. Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 2011;89(6):798-805
27. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target 2010;18(3):157-67
28. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv 2010;10(5):293-304
29. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ ABCG2). Curr Drug Metab 2010;11(7):603-17
30. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 2011;17(26):2793-802
31. Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR. Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity. J Neurochem 2010;115(2):515-25
32. Manda VK, Mittapalli RK, Bohn KA, et al. Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 2010;115(6):1495-507
33. Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for braincancers. J Drug Target 2011;19(9):837-45
34. Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-targeted delivery of Tempol-loaded nanoparticles forneurological disorders. J Drug Target 2010;18(9):665-74
35. Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp 2011;71(1):113-28
36. Vandenhaute E, Sevin E, Hallier-Vanuxeem D, et al. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery. Drug Discov Today 2011; in press
37. DeSalvo MK, Mayer N, Mayer F, Bainton RJ. Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila. Glia 2011;59(9):1322-40
38. Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009;54(3-4):253-63
39. Edwards TN, Meinertzhagen IA. The functional organisation of glia in the adult brain of Drosophila and otherinsects. Prog Neurobiol 2010;90(4):471-97
40. Mayer F, Mayer N, Chinn L, et al. Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci 2009;29(11):3538-50
41. Nielsen PA, Andersson O, Hansen SH, et al. Models for predicting blood-brain barrier permeation. Drug Discov Today 2011;16(11-12):472-5
42. Segalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem Biol 2007;2(4):231-6 (Pubitemid 47629209)
43. Swales LS, Lane NJ. Embryonic development of glial cells and their junctions in the locust central nervous system. J Neurosci 1985;5(1):117-27 (Pubitemid 15155676)
44. Schofield PK, Threherne JE. Localization of the blood-brain barrier of an insect: electrical model and analysis. J Exp Biol 1984;109:319-31
45. Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 2007;30:235-58 (Pubitemid 47218757)
46. Van Itallie CM, Anderson JM. The molecular physiology of tight junction pores. Physiology (Bethesda) 2004;19:331-8 (Pubitemid 39636080)
47. Giacomotto J, Segalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160(2):204-16
48. Stork T, Engelen D, Krudewig A, et al. Organization and function of the blood-brain barrier in Drosophila.J Neurosci 2008;28(3):587-97 (Pubitemid 351159026)
49. Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev 2011;63(2):411-36
50. Dehay B, Bezard E. New animal models of Parkinson's disease. Mov Disord 2011;26(7):1198-205
51. Liu Z, Hamamichi S, Lee BD, et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 2011;20(20):3933-42
52. Bainton RJ, Tsai LT, Schwabe T, et al. moody encodes two GPCRs that regulate cocaine behaviors and blood-brain barrierpermeability in Drosophila. Cell 2005;123(1):145-56 (Pubitemid 41414535)
53. Pinsonneault RL, Mayer N, Mayer F, et al. Novel models for studying the blood-brain and blood-eye barriers in Drosophila. Methods Mol Biol 2011;686:357-69
54. Tan JL, Zon LI. Chemical screening in zebrafish for novel biological and therapeutic discovery. Methods Cell Biol 2011;105:493-516
55. Saydmohammed M, Vollmer LL, Onuoha EO, et al. A high-content screening assay in transgenic zebrafish identifies two novel activators of fgf signaling. Birth Defects Res C Embryo Today 2011;93(3):281-7
56. Rihel J, Schier AF. Behavioral screening for neuroactive drugs in zebrafish. Dev Neurobiol 2012;72:373-85
57. Kawahara G, Karpf JA, Myers JA, et al. Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2011;108(13):5331-6
58. Clifton JD, Lucumi E, Myers MC, et al. Identification of novel inhibitors of dietary lipid absorption using zebrafish. PloS One 2010;5(8):e12386
59. Lessman CA. The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemicallibraries. Birth Defects Res C Embryo Today 2011;93(3):268-80
60. Farrell TC, Cario CL, Milanese C, et al. Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiol Dis 2011;44(1):9-18
61. Jeong JY, Kwon HB, Ahn JC, et al. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res Bull 2008;75(5):619-28
62. Xie J, Farage E, Sugimoto M, Anand-Apte B. A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development. BMC Dev Biol 2010;10:76
63. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16(23):5664-78
64. Carlson SD, Juang JL, Hilgers SL, Garment MB. Blood barriers of the insect. Annu Review Entomol 2000;45:151-74 (Pubitemid 30187858)